March 25, 2020

Dear EB Research Partnership Team,

We are proud to introduce Castle Creek Biosciences, a world-class gene therapy company focused on developing personalized therapies that have the potential to transform the lives of epidermolysis bullosa (EB) patients and their families.

Fibrocell Science was acquired by Castle Creek Pharmaceuticals in December 2019. Now, as one company, we are developing a platform of novel therapies devoted to relieving the pain and suffering of EB among broad patient populations, including those living with recessive dystrophic epidermolysis bullosa (RDEB) and epidermolysis bullosa simplex (EBS). Our headquarters and gene therapy cGMP manufacturing operations are located in Exton, PA, part of greater Philadelphia’s growing life sciences community.

FCX-007, our lead gene therapy candidate, is under evaluation in the DeFi-RDEB Phase 3 clinical trial for the treatment of chronic wounds in RDEB patients. Please visit clinicaltrials.gov and search code NCT04213261 for the study design and enrollment contacts. We presented a poster of our current data at EB2020 in London, which can be found at our website on the “Publications” page (https://castlecreekbio.com/technology/publications/). In addition, CCP-020, a diacerein topical ointment, is being studied in people with EBS, and potentially expanding to other EB subtypes in the future. We will provide updates on both programs as they progress over 2020.

We are committed to continue advancing this research that offers hope to the EB community, and our efforts are supported by a new $75 million investment, primarily directed to support the DeFi-RDEB Phase 3 trial of FCX-007 and to expand our in-house, commercial-scale cGMP infrastructure in preparation for our gene therapy’s potential approval and subsequent launch.

Castle Creek is also growing its staff through 2020 as we progress through the DeFi-RDEB trial and prepare for the future. We have assembled an experienced executive team with a proven record of developing novel and potentially life-changing therapies for diseases with the greatest needs. Our leadership team includes Dr. Mary Spellman, FAAD, Chief Medical Officer, who is leading our clinical and medical operations, and Greg Wujek, Chief Commercial Officer, who is working towards the launch of FCX-007 for patients.

During this time of uncertainty due to COVID-19, we want to confirm that safety is paramount for our employees and their families, and all researchers, patients and caregivers participating in our clinical trials. We are continuing to monitor the impact of this global pandemic, while we remain committed to advancing development of our EB programs.
We are honored to be working with you to develop therapies for EB. Our relationship enables us to connect with EB patients and families to gain a broader perspective on the impact the disease has on their lives and, as a result, has helped us to develop treatments that address critical unmet needs. On behalf of everyone at Castle Creek Biosciences, thank you for your continued support. We value our partnership and remain steadfast in our commitment to you and the EB community and look forward to supporting future events. For more information, please visit us at castlecreekbio.com.

Sincerely,
John Maslowski
Chief Executive Officer